key: cord-0743738-jw9huvy9
authors: Hajjo, Rima; Sabbah, Dima A.; Bardaweel, Sanaa K.
title: Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19
date: 2020-11-12
journal: ACS Omega
DOI: 10.1021/acsomega.0c03597
sha: dafe4937d4bff3b9cc9f75d3a36611bb38a7b4b3
doc_id: 743738
cord_uid: jw9huvy9

[Image: see text] COVID-19 is a biphasic infectious disease with no approved vaccine or pharmacotherapy. The first drug that has shown promise in reducing COVID-19 mortality in severely-ill patients is dexamethasone, a cheap, well-known anti-inflammatory glucocorticoid, approved for the treatment of inflammatory conditions including respiratory diseases such as asthma and tuberculosis. However, about 80% of COVID-19 patients requiring oxygenation, and about 67% of patients on ventilators, are not responsive to dexamethasone therapy mainly. Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure. In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of the drug, we applied a chemocentric informatics approach to identify combination therapies. Our results indicated that combining dexamethasone with fast long-acting beta-2 adrenergic agonists (LABAs), such as formoterol and salmeterol, can ease respiratory symptoms hastily, until dexamethasone’s anti-inflammatory and immunosuppressant effects kick in. Our studies demonstrated that LABAs and dexamethasone (or other glucocorticoids) exert synergistic effects that will augment both anti-inflammatory and fibronectin-mediated anticoagulant effects. We also propose other alternatives to LABAs that are supported by sound systems biology evidence, such as nitric oxide. Other drugs such as sevoflurane and treprostinil interact with the SARS-CoV-2 interactome and deserve further exploration. Moreover, our chemocentric informatics approach provides systems biology evidence that combination therapies for COVID-19 will have higher chances of perturbing the SARS-CoV-2 human interactome, which may negatively impact COVID-19 disease pathways.

COVID-19 is a highly infectious disease that can result in severe comorbidities, especially acute respiratory distress syndrome (ARDS). 1 There is no treatment or vaccine that has been approved for this disease yet. The first drug that has shown value in reducing COVID-19-related morbidity and mortality is the anti-inflammatory glucocorticoid receptor (GCR) agonist, dexamethasone.

The RECOVERY trial 2 which is a randomized, controlled, open-label, adaptive, platform trial, comparing a range of possible treatments for hospitalized COVID-19 patients, has recently shown positive preliminary results for using dexamethasone. 3 The study has found that dexamethasone reduced deaths in patients on ventilators by one-third and by one-fifth in patients who required oxygen only. As a result, the WHO announced dexamethasone as the first drug to improve survival in COVID-19 patients with severe respiratory complications. 4 Dexamethasone is also an FDA-approved adjuvant drug for the treatment of tuberculosis 5 caused by Mycobacterium tuberculosis (Mtb), a pathogen that has a very similar human interactome to SARS-CoV-2. 6 In their recent research article published in Nature, Gordon et al. noted that this similarity is noteworthy considering that both pathogens are intracellular and cause lung-related pathologies. Hence, this is an interesting finding that dexamethasone has shown efficacy in treating tuberculosis and COVID-19 patients.

Glucocorticoids are polypharmacological 7−13 drugs with numerous indications. 14 They are used commonly as adjuvant therapies to treat severe cases of influenza 15 and have shown positive therapeutic effects in ARDS. 16 Glucocorticoids are known to modulate cytokine responses, induce apoptosis, 17 and regulate the cellular functions of immune and nonimmune cells including T-cells, macrophages, eosinophils, neutrophils, mast cells, and endothelial and epithelial cells. 5 In addition, corticosteroids affect blood vessels through adrenergically mediated vasoconstriction and noncompetitive antagonism of vasodilation because of prostaglandin E and bradykinin. 18 Dexamethasone, like other glucocorticoids, exerts its effects on the lungs and vasculature, through genomic 19 and nongenomic mechanisms. 20 Genomic effects are delayed because they involve the regulation of gene expression and the downregulation of genes involved in airway inflammation and angiogenesis. On the other hand, nongenomic actions occur immediately after drug administration and are mediated by swift cellular mechanisms that induce transient vasoconstriction in respiratory airways to reverse inflammatory hyperperfusion. 20 However, dexamethasone is not an optimal treatment for COVID-19 patients, at least not as a single therapy. First, dexamethasone does not benefit patients with mild symptoms, and it may actually worsen the disease course if it was administered very early when symptoms first appear. 21 Although there is an agreement on the fact that COVID-19 is a biphasic disease requiring different treatments in each phase, dexamethasone is not effective in relieving respiratory distress in the majority of severe COVID-19 cases experiencing the overreactive inflammatory stage of the disease. Second, the antiinflammatory and immunosuppressant effects of dexamethasone may take days 22 before exerting notable therapeutic effects on COVID-19 patients, especially when using low doses of dexamethasone as this is the case in the RECOVRY trial, which may harm some patients who cannot fight the disease that long.

It has been reported that the administration of high-dose glucocorticoid treatment could accelerate the recovery from ARDS; 16 however, the therapeutic effects of glucocorticoids in COVID-19-related ARDS patients are uncertain. 1 Therefore, we suggest that combination therapies consisting of dexamethasone #  regimen  name  type  drug status  source  status   1  single agent  dexamethasone a  small molecule  CTphase IV  NCT01731795  completed  2  single agent  sevoflurane  small molecule  CTphase IV  NCT02166853  completed  3  combination  budesonide a  small molecule  CTphase II  NCT01783821  completed  formoterol  small molecule  4  single agent  treprostinil  small molecule  CTphase II  NCT02370095  recruiting  5  single agent  methylprednisolone a  small molecule  CTphase II/III  NCT00562835  unknown status  6  single agent  depelestat  biologic  CTphase II  NCT00455767  completed  7  single agent  ALT-836  biologic  CTphase II  NCT00879606  completed  8  single agent  molgramostim  biologic  CTphase II  NCT02595060  recruiting  9 single (or other glucocorticoids as alternatives) and a drug that has shown promise in relieving ARDS in clinical trials (CTs) ( Table  1) can potentially treat ARDS in COVID-19 patients. Based on our analysis, one promising example may be combining glucocorticoids (i.e., dexamethasone, methylprednisolone, and budesonide) with a long-acting beta-2 adrenergic agonist (LABA) drug such as formoterol. Such a combination may yield better clinical outcomes in COVID-19 patients; dexamethasone will suppress inflammatory and immune responses with time, 16 and LABAs will exert immediate bronchodilatory and vasodilatory effects 23, 24 rescuing patients with severe inflammatory-active COVID-19.

2. RESULTS AND DISCUSSION 2.1. Dexamethasone's Polypharmacology and Its Effects on COVID-19 Pathways. Several lines of systems biology evidence highlighted important polypharmacological effects of dexamethasone that may impact COVID-19 pathogenesis and viral disease pathways. The evidence has been established based on (1) chemical−protein interaction networks for dexamethasone; (2) protein−protein interactions (PPIs) for the GCR; and (3) gene expression profiles of dexamethasone and dexamethasone mimics.

2.1.1. CPI Network for Dexamethasone. To get a better understanding of possible therapeutic mechanisms of dexamethasone in COVID-19, we generated a high-confidence functional dexamethasone−protein interaction network ( Figure  1 ) using high-confidence protein interactions with dexamethasone extracted from the biomedical literature and deposited in STRING. 25 Over-representation analysis of all proteins in the dexamethasone−protein interaction network indicated that these proteins are over-represented in cytokine and interleukin inflammatory pathways, which is an expected result based on our understanding of GCR agonists and their pharmacological effects.

2.1.2. Physical PPIs for the GCR. Physical human PPIs for the GCR, that is, the human GCR interactome, were extracted from BioGRID. 26 All physical PPIs for the GCR (NR3C1) are reported in the Supporting Information Table S1 .

2.1.3. Dexamethasone Mimics Reveal Important Biological Pathways. We used two gene signatures for dexamethasone to query the connectivity map (CMap) and identify dexamethasone mimics. We define mimics as compounds or genetic perturbations that produce similar gene expression signatures using the (CMap) approach. 27−29 The CMap approach ranks all compounds in the database according to their gene expression similarity to dexamethasone's gene signatures. Results for top scoring positive and negative connections are shown in the Supporting Information Figure  S1 . Positive connections are compounds or genetic perturbations that produce gene expression signatures similar to the gene signature of the query compound, that is, dexamethasone. Negative connections are compounds or genetic perturbations that produce gene expression signatures that are anticorrelated with the gene signature of the query compound.

As we are interested in treating a lung condition, that is, ARDS, we focused on the alveolar cell line A549 which overexpresses the GCR (NR3C1). We also analyzed gene expression data for dexamethasone from the prostate cancer cell line VCAP to assess dexamethasone's effects in biological contexts that downregulate the GCR, that is, as a control. CMap results revealed that dexamethasone generates a characteristic glucocorticoid agonist gene signature in the A549 cell line, and this signature is very similar to gene signatures produced by progesterone receptor agonists, sirtuins gain of function (GOF) genetic perturbations, aromatase inhibitors, and, to a lesser extent, HSP inhibitors. However, dexamethasone's gene signature in the prostate cancer cell line VCAP, which downregulates GCRs and upregulates androgen receptors (ARs), resembles that of a p38 MAPK inhibitor. Actually, p38 MAPK belongs to the mitogen-activated protein kinases (MAPKs) which are key regulators of signaling cascades that are activated by cytokines, growth factors, stress, and viral infections, 30, 31 and it has been suggested recently as a therapeutic strategy for COVID-19. 32 One conclusion from this analysis is that dexamethasone's effects on p38 MAPK signaling are more pronounced in biological contexts with active AR signaling. RNA expression data for GCR (NR3C1), ADRB2, and AR, across a panel of cell lines reported in the Human Protein Atlas (HPA) project, 33 are shown in the Supporting Information Figure S2 .

Our results confirm that dexamethasone's effects vary in different biological contexts that are exposed to or deprived from AR signaling and this may cause gender-based differences in response to dexamethasone treatments in lung disease; male patients will have more complications because they have a higher level of p38 MAPK signaling because of the agonistic effects of male androgens on ARs of the lung tissues. In fact, there is a large body of evidence in the biomedical literature highlighting considerable sex differences in respiratory physiol- CoV-2 interactome  reference   1  budesonide  NR3C1  ABCC1, IDE, IL17RA, GNB1, HDAC2, LARP7, NUP210, NUP54,  TLE3   NCT01783821   2  dexamethasone  NR3C1  ABCC1, IDE, IL17RA, GNB1, HDAC2, LARP7, NUP210, NUP54,  TLE3   NCT01731795   3  methylprednisolone NR3C1  ABCC1, IDE, IL17RA, GNB1, HDAC2, LARP7 ogy and in the response of the lung to environmental agents 34−39 and that such differences are partly mediated by sex hormones and their nuclear receptors. 40 Another important finding from the CMap analysis is the identification of variable gene signatures for different glucocorticoids. This means that glucocorticoids may have varying effects on COVID-19 patients because they induce different gene expression profiles.

2.2. Initial List of Candidate Drugs for COVID-19 Combination Therapy. A small proportion (8−15%) of all COVID-19 patients will progress to develop severe illness including respiratory failure, ARDS, multiple organ failure, and potentially death. 41 Therefore, drug discovery efforts should focus the efforts on finding effective therapeutic options for this patient population until an effective SARS-CoV-2 antiviral or vaccine is available. Herein, we propose that the first go-to list of drug candidates for combination therapy should be drugs that have shown promise in relieving non-COVID-19 ARDS. This is in fact, the same reason why dexamethasone itself was considered as a possible treatment for COVID-19 patients in the first place, 42 as it reduces ARDS-induced mortality under non-COVID-19 respiratory conditions. 16 First, we mined all drugs that are currently undergoing clinical trials for ARDS, from clinicaltrials.gov, 43 and all results are shown in Table 1 . Next, we filtered the initial list and accepted only small-molecule drugs that we can interrogate later using systems biology tools. Additional filtering step was performed by removing all small-molecule drugs that failed in clinical trials (i.e., "terminated" or "withdrawn", Table 1 ). The candidate drugs that remained after this initial filtering were budesonide, dexamethasone, methylprednisolone, formoterol, sevoflurane, and treprostinil. We also added salmeterol and nitric oxide to the list of candidate combination drugs in Table 2 . Salmeterol is known to alleviate disease symptoms under respiratory conditions such as asthma, 23 chronic obstructive pulmonary disease (COPD), 44 and tuberculosis. 45 Nitric oxide (NO) is an effective pulmonary vasodilator that has shown partial beneficial therapeutic effects in COVID-19. 46, 47 Also, inhaled nitric oxide is still used extensively worldwide as a rescue agent in severely hypoxemic patients with ARDS. 48, 49 Table 2 summarizes all promising small-molecule drug candidates that we suggest combining with dexamethasone to treat the severe cases of COVID-19.

Two of the non-glucocorticoid candidate drugs for combination with glucocorticoids, that is, formoterol and salmeterol, are beta-2 adrenergic receptor (ADRB2) agonists that are classified as fast LABAs. This class of compounds is considered a very promising combination option with glucocorticoids to relieve respiratory distress and rescue COVID-19 patients. We will discuss all the evidence supporting LABA use for COVID-19 patients in the following sections.

Treprostinil, a synthetic analogue of prostacyclin (also called prostaglandin I2 or PGI2), is indicated for the treatment of pulmonary arterial hypertension. 50 The use of inhaled prostacyclin analogues has been shown to enhance oxygenation in severe refractory hypoxic respiratory failure. 51 The prostacyclin analogue treprostinil appears to improve the oxygenation level and thus may have positive outcomes in patients at high risk for ARDS. 52 Recently, inhaled treprostinil was reported to improve a 6 min walk test in patients with pulmonary arterial hypertension (PAH) and infected with COVID-19. 53 Additionally, volatile anesthetics (e.g., sevoflurane) are reported to have immune modulating effects that may diminish death signals and the successive inflammatory cascade. 54 The potential benefits of volatile anesthetics in animals and patients with ARDS have been addressed in several clinical trials. In a recent clinical trial, Jabaudon and colleagues 55 reported the effects of sevoflurane sedation in ARDS patients to improve the PaO2/FiO2 ratio and decrease interleukin-6 and TNF-a. Currently, there are several clinical trials 56 to study the effect of sevoflurane sedation on mortality and persistent organ dysfunction (POD) in patients suffering from COVID-19 ARDS.

Nitric oxide is a natural antimicrobial and a potent vasodilator that has proved to be effective in reducing SARS-CoV replication and hypoxia in patients with severe acute respiratory syndrome (SARS). 57 Nitric oxide binds and inhibits SARS-CoV-2 3CL recombinant protease in vitro. 58 Recent clinical studies indicated that nitric oxide dosed in short bursts at high concentrations may protect against COVID-19. 59 2.3. Systems Biology Support for Combination Therapy in COVID-19. After we identified all potential compounds for combination therapy for COVID-19 ARDS (Table 1) , we filtered candidate small-molecule drugs and listed them in Table 2 . In this section, we will interrogate all candidate drugs for combination with glucocorticoids using systems biology approaches in order to prioritize the highest-confidence combinations that produce synergistic interactions or other beneficial network interactions. The workflow for filtering and prioritizing combination drugs is shown in Figure 2. 2.3.1. Effects on COVID-19 Molecular Pathways. In order to identify the strongest hypothesis from all combination drug candidates listed in Table 2 , we mined all MetaCore pathway maps that contain any of the primary drug targets reported in Table 2 : NR3C1, ADRB2, GABRA1, GLRA1, GRM1, ATP2C1, GABAA, KCNMA1, PTGIR, PPARD, P2Y12, and GUCY1A2. We prioritized an initial list of 61 pathway maps (Supporting Information Table S2 ). Then, we subjected these maps to an additional filtering step by keeping disease maps that may explain the pathogenesis of COVID-19 from the initial list. Finally, we had 17 pathway maps (Supporting Information Table S3 ) that belong to three main ontology categories: (1) disease maps for lung disease; (2) disease maps for viral and 2.3.2. Effects on the Human SARS-CoV-2 Interactome. Combination therapy impacts SARS-CoV-2 more than dexamethasone alone. In order to assess the putative therapeutics effects of combination therapies on COVID-19 patients, dexamethasone and all drugs suggested for combination therapy with dexamethasone were compared based on their predicted overlaps with the SARS-CoV-2 human interactome. All human proteins making physical interactions with dexamethasone's primary human target GCR were mined from BioGrid 26 and STRING 25 databases. Next, we compared the human interactomes of dexamethasone and SARS-CoV-2 and identified 9 overlapping proteins: ABCC1, IDE, IL17RA, GNB1, HDAC2, LARP7, NUP210, NUP54, and TLE3 (Table 2 ). This means that dexamethasone, through its action on the GCR, impacts the SARS-CoV-2 human interactome at 9 different proteins.

In order to evaluate the drug candidates suggested for combination therapy, herein, we determined the primary human targets of these compounds and determined the overlaps between the SARS-CoV-2 human interactome and the human Figure 3 . Glucocorticoid-and LABA-mediated inhibition of proinflammatory signaling in airway fibroblasts/myofibroblasts. This map is generated using MetaCore's Pathway Map Creator starting with an already existing map to focus on GCR and beta-2 adrenergic receptor. B: binding; IE: influence on expression; TR: transcription regulation; and red arrows for inhibition, green arrows for activation, gray arrows for unspecified action, violet text boxes for normal process, pink text boxes for pathological processes, blue text boxes for notes, and starred network objects refer to groups or complex processes.

interactomes of the proposed drugs. All results are shown in Table 2 .

2.3.3. Combined Systems Biology Evidence to Prioritize Combination Therapy Hypotheses. Herein, we integrated systems biology evidence to prioritize the most promising combination from the eight drugs shown in Table 2 . First, we identified which drugs have synergistic interactions with glucocorticoids at the systems biology level. This step was performed by mining all MetaCore's pathway maps that include glucocorticoids/GCR and all other drugs plus the primary targets listed in Table 2 . From 17 filtered disease maps, we identified two pathway maps that showed favorable synergistic therapeutic effects for glucocorticoids and LABAs: (1) for reducing proinflammatory signaling in airway fibroblasts/ myofibroblasts ( Figure 3) and (2) for the putative antifibrotic effects (Figure 4) .

This combination is known for its anti-inflammatory effects; 60−63 LABA induces GCR activation probably via beta- influence on expression; TR: transcription regulation; and red arrows for inhibition, green arrows for activation, gray arrows for unspecified action, violet text boxes for normal process, pink text boxes for pathological processes, blue text boxes for notes, and starred network objects refer to groups or complex processes.

2 adrenergic receptor/G-protein alpha-s/Cyclic AMP/PKA-reg (cAMP-dependent)/PKA-cat (cAMP-dependent) signaling, as shown in Figure 3 . This induction of the beta-2 adrenergic receptor becomes very essential for ARDS patients who have downregulated GCRs in response to increased AR activation by androgens. Eventually, patients may suffer from the consequences of the reduced inhibition of NF-kB signaling in response to GCR downregulation. This entails the lack of antiinflammatory activity in responses to elevated doses of dexamethasone or other glucocorticoids. 64, 65 Therefore, LABA can rescue anti-inflammatory signaling by exerting non-GCR anti-inflammatory and antifibrotic effects (Figures 3 and 4) .

Another advantage for this combination therapy is the faster action of LABA in comparison with that of dexamethasone; 66, 67 therefore, LABA will start reversing proinflammatory signaling relatively early before the damage becomes irreversible.

Another positive therapeutic outcome of using combination therapy of LABA and glucocorticoids is the putative antifibrotic action resulting from the inhibitory effects on the transforming growth factor beta-1 (TGFB1) signaling in airway fibroblasts and myofibroblasts, which reduces fibronectin production eventually.

Thus, we suggest that a combination therapy comprising GCR agonists and LABA would be a promising therapeutic option for COVID-19 patients. Besides, their well-known antiinflammatory activity, glucocorticoids and LABA may also exert synergistic antifibrotic action by inhibiting TGFB1 signaling in airway fibroblasts and myofibroblasts (Figure 4) , although this effect on the airway remodeling process is not well-understood and red arrows for inhibition, green arrows for activation, gray arrows for unspecified action, violet text boxes for normal process, pink text boxes for pathological processes, blue text boxes for notes, and starred network objects refer to groups or complex processes. at the moment. Remarkably, experiments reported in the biomedical literature showed that glucocorticoids, beclomethasone specifically, reduced TGFB1-induced fibronectin production, only when they were combined with LABAs (e.g., formoterol and salmeterol). 68 This may apply to other glucocorticoids used in combination with LABAs.

Another promising combination comprises a glucocorticoid drug plus nitric oxide. Although we could not identify pathway maps with established synergy or other beneficial network interactions between glucocorticoids and nitric oxide, our systems biology evidence indicates that combining a glucocorticoid with nitric oxide can potentially protect from airway occlusion because of mucus overproduction, which may happen in COVID-19 patients. It is known that mucus is a critical component of the innate host defense system in the respiratory tract and its production by goblet cells increases in response to lung injury. 69 Although mucus is thin and clear under normal physiological conditions, however, under certain pathological conditions associated with alveolar damage and airway metaplasia, mucin-5AC (MUC5AC) expression is activated resulting in excessive mucus production and subsequent airway occlusion. 70 Mucus hypersecretion and mucous metaplasia are hallmarks of chronic airway diseases, including COPD. 71, 72 The recent pathological findings in COVID-19 patients indicated that the inflammatory phase of the disease manifested as hypersensitivity pneumonitis rather than viral pneumonitis. 73 Thus, SARS-CoV-2 can be considered as an allergic antigen for respiratory mucosa which stimulates mucus secretion and alters its chemical structure to enhance the entry of the virus into cells. 74 It was these findings that encouraged clinicians to add dexamethasone to the treatment options of COVID-19. 73, 74 Additionally, pulmonary postmortem findings in a series of COVID-19 cases from northern Italy indicated that patients showed features of type 2 pneumocyte hyperplasia (in all 38 study cases) and squamous metaplasia with atypia (in 21 out of 38 cases). 75 These pathological features seen in deceased COVID-19 patients validated the importance of combinations (i.e., glucocorticoids and nitric oxide) that can interact to relieve or minimize airway occlusion in COVID-19 patients by reducing excessive mucus production in response to alveolar damage in the lungs. 76 Our systems biology analysis showed that when nitric oxide binds and activates its primary target, guanylate cyclase, it induces MUC5AC overexpression which stimulates the secretion of mucin from the goblet cell and submucosal glands. On the other hand, glucocorticoids are known to affect mucus production and secretion through activating GCRs which leads to MUC5AC transcription inhibition reducing excessive mucus production. 77, 78 Details describing the systems biology support for this combination are summarized in terms of a pathway map shown in Figure 5 , which has been generated using MetaCore's Pathway Map Creator starting with an already existing non-COVID-19 pathology map for Th2-cytokine-induced airway epithelium mucous metaplasia in COPD (Supporting Information Figure S3 ). The original disease map for COPD has been simplified by hiding upstream signaling events affecting this pathway above GCR and guanylate cyclase. The modified map focuses on connections between nitric oxide (which was on the original map) and a glucocorticoid (e.g., dexamethasone) which has been included in the modified map in Figure 5 by adding the GCR as a new seed that has numerous connections with previous seeds on the original map. As we can see, GCR activation by glucocorticoids decreases MUC5AC expression activation, limiting the activating effects on mucus production caused by nitric oxide which can rescue COVID-19 patients with pneumocyte hyperplasia or metaplasia.

The systems biology support for glucocorticoid−sevoflurane or glucocorticoid−treprostinil remains less mature than the evidence supporting the glucocorticoid−LABA or glucocorticoid−nitric oxide combinations. However, the interactions of Figure 7 . Predicted dexamethasone/LABA and SARS-CoV-2 protein interactomes. The network represents a merged network involving NR3C1 and ADRB2 PPI networks of proteins (i.e., nodes) known to be part of the SARS-CoV-2 human interactome. Nodes were clustered using K-means clustering setting the number of clusters to 4 and colored as red, blue, green, and yellowish-green. Edge colors and shapes represent action times and effects, respectively, and are explained in the legend included at the bottom of the figure. Nodes that are colored with an outer-colored frame represent proteins that interact with SARS-CoV-2 proteins according to the legend in the bottom of the figure. sevoflurane and treprostinil with the SARS-CoV-2 interactome, through their primary targets, are significant and should not be overlooked (Table 2) . However, more evidence from pathological studies and various in vivo studies is needed to support these findings.

The next piece of systems biology evidence, supporting the use of LABA and glucocorticoid combination therapy for COVID-19, relies on an increased number of PPIs of the combination, with the SARS-CoV-2 human interactome, as opposed to single treatments of LABAs or glucocorticoids. Besides, glucocorticoids and LABAs may have synergistic effects on GNB1 and NUP210 because these two proteins are modulated by both GCR and ADRB2 and are known to interact with SARS-CoV-2 proteins (Figures 6 and 7) . In fact, NUP210 has been found to affect T Cell responses 79, 80 that are required to combat SARS-CoV-2 and other viruses.

2.4. Literature Support. Evidence from clinical studies 23,24,60,61 indicated that asthma and COPD patients who are treated with a combination therapy comprising a LABA and inhaled glucocorticoid (e.g., dexamethasone) will result in a better lung function, an increased symptom control, and reduced exacerbations compared with those that were given either LABAs or glucocorticoids alone. 23, 24, 63, 81, 82 3. DISCUSSION COVID-19 is viewed as a biphasic 60,61 infectious disease that can cause death by inducing lung failure because of severe ARDS in susceptible human subjects. 83 The first phase of the disease involves viral reproduction and the spread of infection, while the second phase of the disease is inflammatory leading to severe respiratory distress in some cases which require hospitalization (about 20% of symptomatic confirmed COVID-19 patients) or may need intensive care and will most likely require ventilators (about 20% of symptomatic confirmed COVID-19 patients). Lung fibrosis induced by the activation of transforming growth factor-beta (TGF-β) signaling is usually the main cause of non-COVID-19 ARDS, including ARDS caused in response to SARS-CoV infections. 84 This mechanism is very likely to be the main driver for ARDS in COVID-19, too. 85 Dexamethasone is the first FDA-approved drug that has been proven to reduce COVID-19 mortality in severely-ill patients requiring oxygen supply either with or without mechanical ventilators. 3, 42, 86 However, dexamethasone's therapeutic effects may take long time to kick in, requiring an additional drug that can ease ARDS symptoms promptly. Therefore, we examined all mined drugs that are undergoing clinical trials for ARDS and listed them in Table 1 . Then, we filtered this initial list of compounds and accepted only small-molecule drugs that have not been terminated or withdrawn from use and that we can interrogate using our chemocentric informatics workflow. This filtering increased our confidence in the selected candidate drugs for COVID-19 ARDS ( Table 2 ). The only drug that we included in this list that was not in Table 1 is nitric oxide. The rationale for including this drug was that we had three. Additionally, nitric oxide is currently being examined as a single therapy for COVID-19 ARDS (clinical trial ID: NCT04445246).

Our research findings indicate that dexamethasone's therapeutic effects in COVID-19 patients can occur mostly through genomic mechanisms, although immediate nongenomic mechanisms are likely, especially when higher doses of the drug are used. 16 In fact, it is not possible to separate genomic and nongenomic effects clinically. 87 However, the anti-inflammatory and immunosuppressive effects happen over time in response to low doses of dexamethasone used in the treatment of COVID-19 patients. 3 Thus, dexamethasone can minimize the impact of the inflammatory phase of the disease by averting the cytokine storm caused by the severe forms of SARS-CoV-2 infection.

Additionally, our systems biology analysis showed that dexamethasone can inhibit fibronectin production through activating p38 mitogen-activated protein kinase (p38 MAPK), which reduces coagulation problems. The proposed mechanism of dexamethasone-mediated inhibition of fibronectin production is rationalized in Figure 4 , which entails the inhibition of fibronectin production by a GCR-mediated inhibition of "mothers against decapentaplegic homologue 3" (SMAD3). 88,89 SAMD3 inhibition will result in the deactivation of transcription factor SP1 (SP1) and, therefore, reduce fibronectin production. 90, 91 Herein, we have prioritized combination therapies by combining dexamethasone with other drugs that have been shown to relieve ARDS in clinical trials. We propose that combination therapies composed of glucocorticoids (e.g., dexamethasone) and LABAs, or glucocorticoids and nitric oxide, might be better alternative treatments to COVID-19 than the mono-dexamethasone therapy. Our rationale is based on fact that dexamethasone's anti-inflammatory effects are induced by genomic modifications and will take time to kick in, and therefore, a second therapeutic agent such as LABA, nitric oxide, or other drugs presented in Table 2 may be able to act rapidly and rescue patients before dexamethasone exerts its therapeutic effects.

In this paper, we provide systems biology support showing that combination therapy is better than monodexamethasone therapy. Our conclusions relied on combining evidence from multiple systems biology approaches, which indicated that (1) combination therapies have favorable synergistic effects on putative COVID-19 disease pathways; (2) combination therapies have higher chances to modulate viral disease pathways by interacting with larger numbers of viral proteins that constitute the human SARS-CoV-2 interactome; (3) drugs such as LABA, sevoflurane, treprostinil, and nitric oxide can immediately ease the respiratory symptoms before the delayed dexamethasone's anti-inflammatory effect starts.

Our combined systems biology evidence prioritized the use of LABAs, such as formoterol and salmeterol, with dexamethasone (or other GCR agonists) as the first choice based on all available systems biology and literature support. Our results also indicate that the fast long-acting bronchodilators, formoterol and salmeterol, can minimize the acute respiratory distress symptoms associated with the severe phase of COVID-19, while the underlying inflammation is being treated gradually over time with low doses of dexamethasone. Consequently, this combination may have better chances to treat the disease more efficiently while minimizing the potential for developing serious side effects including drug resistance. Additional support from the literature indicated that the combination of LABAs and glucocorticoids is much better than either class of drugs alone in other severe lung disorders. Previous studies found that fibrocytes from severe asthmatic patients are relatively insensitive to the therapeutic effects of single therapy of salmeterol or dexamethasone. However, a combination of LABAs with glucocorticoids is more effective in suppressing fibrocyte numbers and differentiation than each drug alone. 92 The same scenario might be applicable to COVID-19 patients who develop respiratory distress and require oxygenation.

4.1. Integrative Informatics Workflow. We applied a chemocentric informatics approach developed by Hajjo et al. 93, 94 to study dexamethasone's network pharmacology and prioritize combination therapy for COVID-19 patients. 94, 95 This workflow has been used recently to prioritize pharmacotherapy for COVID-19. Our workflow incorporates three major components: (1) a module for mining and prioritizing gene signatures in response to drug/chemical treatment; (2) a network-mining module to identify chemical compounds that induce gene expression profiles to a signature of interest; and (3) a pathway enrichment module to understand the biological processes involved in the mechanism of action of dexamethasone and highly correlated genetic perturbagens.

4.2. Data Curation. All gene names were adjusted according to HUGO nomenclature rules 95,96 before querying databases of gene expression and biological pathways.

4.3. Cytoscape Network Building Tools. A systematic search for dexamethasone−protein interactions was conducted in Cytoscape 97 version 3.8.0 using the STRING 25 protein query application. All PPIs, including both physical and functional interactions, were retrieved from popular databases such as MINT, 98 HPRD, 99 BIND, 100 DIP, 101 BioGRID, 26 KEGG, 102 Reactome, 103 EcoCyc, 104 NCI-Nature Pathway Interaction Database, and Gene Ontology (GO) 105 . This database of cellular signatures has been generated using the L1000 platform, 27 a high-throughput gene expression assay that measures the mRNA transcript abundance of 978 "landmark" genes from human cells.

4.5. Dexamethasone Gene Signatures. Two gene expression signatures for dexamethasone obtained from the CMap databases were used as query signatures, to query the CMap databases and identify drugs and genetic perturbations that mimic dexamethasone effects on gene expression (i.e., highly correlated) or reverse dexamethasone effects on gene expression (i.e., anticorrelated). 4.6. MetaCore. MetaCore version 20.3 build 70200 from Clarivate Analytics is a database of manually composed ontologies mapped to canonical pathways and networks. We used this database for purposes of enrichment analysis in pathway maps. Pathway maps in MetaCore are defined as subsets of genes that are connected with each other to describe a specific cellular process in a specific cellular context. Herein, the enrichment analysis is performed by examining the intersection between the gene signature and the prebuilt pathway maps in MetaCore using the hypergeometric mean which takes into account the number of objects in your dataset, the number of objects in the intersecting map, and the number of objects in the entire database. This assessment returns a p-value that tells us the likelihood that the intersection between the gene signature and a particular map is obtained purely by chance. We set the pvalue threshold at 0.05; rejecting all hypotheses/pathway maps that have enrichment p-values higher than 0.05.

We also used the Pathway Map Creator version 2.6.0 from MetaCore to generate high-quality pathway maps capable of explaining the beneficial effects of potential combination therapies for COVID- 19. 4.8. Enrichment Analysis. Enrichment analysis was conducted in Cytoscape 97 and MetaCore to identify pathways and biological processes associated with dexamethasone. The significance of the enrichment was determined by the hypergeometric test. 106 All terms from the ontology are ranked based on their calculated p-values. Ontology terms with p-values less than the p-value threshold 0.05 are defined as statistically significant and therefore relevant to the studied list of genes. All terms from the ontology are ranked according to their calculated p-values.

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.0c03597.

CMap connections for dexamethasone: GOF refers to gene's GOF and LOF refers to gene's loss of function; RNA expression data generated in the HPA project; and pathway map for Th2-cytokine-induced airway epithelium mucous metaplasia in COPD (PDF) Physical PPIs for the GCR; all analyzed pathology pathway maps that are relevant to the primary drug targets of ARDS drugs; and filtered pathology pathway maps that overlap with lung disease pathways, bacterial/ viral infection pathways, or disease pathways including the drug and xenobiotic mechanism of action (XLSX) 

Acute respiratory failure in COVID-19: is it "typical" ARDS?

2020. (4) WHO. WHO Welcomes Preliminary Results About Dexamethasone Use in Treating Critically ill COVID-19 Patients

Novel adjunctive therapies for the treatment of tuberculosis

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Ocular side-effects of topical corticosteroids: what a dermatologist needs to know

Intravenous dexamethasone as an analgesic: A literature review

A narrative review of the evidence on the efficacy of dexamethasone on postoperative analgesic consumption

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Corticosteroids as Adjunctive Therapy in the Treatment of Influenza

Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature

Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes

Anti-inflammatory action of corticosteroids

Effects of glucocorticoids on gene transcription

Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma

Report: Disseminated Strongyloidiasis in a Patient with COVID-19

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

The BioGRID interaction database: 2008 update

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality

Innate defense regulator IDR-1018 activates human mast cells through G protein-, phospholipase C-, MAPK-and NF-KB-sensitive pathways

Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells

p38 MAPK inhibition: A promising therapeutic approach for COVID-19

The human protein atlas: A spatial map of the human proteome

The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies

It's all about sex: gender, lung development and lung disease

Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women

Role of Estrogen Receptors α and β in a Murine Model of Asthma: Exacerbated Airway Hyperresponsiveness and Remodeling in ERβ Knockout Mice

Sex-Specific Regulation of Gene Expression Networks by Surfactant Protein A (SP-A) Variants in Alveolar Macrophages in Response to Klebsiella pneumoniae

Gender differences in health: a Canadian study of the psychosocial, structural and behavioural determinants of health

Hormonal influences on lung function and response to environmental agents: lessons from animal models of respiratory disease

novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

Adult respiratory distress syndrome

Salmeterol/fluticasone combination in the treatment of COPD

Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation

Home Nitric Oxide Therapy for COVID-19

Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection

Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults

Survey of interventions for the prevention and treatment of acute respiratory distress syndrome*

Treprostinil for the treatment of pulmonary hypertension

Approaches to refractory hypoxemia in acute respiratory distress syndrome: current understanding, evidence, and debate

Risk stratification and medical therapy of pulmonary arterial hypertension

Inpatient Use of Inhaled Pulmonary Vasodilator Therapy in Patients Infected With COVID-19

Immune modulation by volatile anesthetics

Sevoflurane for sedation in acute respiratory distress syndrome. A randomized controlled pilot study

Sevoflurane|Covid19

Nitric oxide synthases: roles, tolls, and controls

Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro

Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

Risk Profile of Budesonide in Obstructive Airways Disease. Drugs

New therapies for asthma and chronic obstructive pulmonary disease

Interactions between Corticosteroids and 2-Agonists in Asthma and Chronic Obstructive Pulmonary Disease

Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells

Molecular Mechanisms of Combination Therapy With Inhaled Corticosteroids and Long-Acting β-Agonists

Long-acting beta-agonists and their association with inhaled corticosteroids in COPD

Assessing the clinical value of fast onset and sustained duration of action of longacting bronchodilators for COPD

Anti-proliferative and antiremodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts

Airway mucus function and dysfunction

Regulation of airway mucin gene expression

Mucociliary clearance in the airways

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer

A hypothesis on the role of the human immune system in covid-19

Pulmonary postmortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Glucocorticoid Receptor and Histone Deacetylase-2 Mediate Dexamethasone-Induced Repression ofMUC5ACGene Expression

Expression in Human Lung Epithelial Cells

Nuclear pore complex-mediated modulation of TCR signaling is required for naive CD4+ T cell homeostasis

Mice Deficient in Nucleoporin Nup210 Develop Peripheral T Cell Alterations

Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma

Salmeterol for the prevention of high-altitude pulmonary edema

Clinical progression of patients with COVID-19 in Shanghai

SARS coronavirus and lung fibrosis

Platelet-Derived Growth Factor and Transforming Growth Factor β1 Regulate ARDS-Associated Lung Fibrosis Through Distinct Signaling Pathways

Low-Cost Dexamethasone Reduces Death by up to One Third in Hospitalised Patients with Severe Respiratory Complications of COVID-19

Genomic and non-genomic actions of glucocorticoids in asthma

Identification of Glucocorticoid Receptor Domains Involved in Transrepression of Transforming Growth Factor-β Action

Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3

Glutathione redox regulates TGF-β-induced fibrogenic effects through Smad3 activation

TGF-β-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing

Reduced suppressive effect of β(2)-adrenoceptor agonist on fibrocyte function in severe asthma

Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers

Sitagliptin: A potential drug for the treatment of COVID-19

Genenames. org: the HGNC and VGNC resources in 2019

Cytoscape: a software environment for integrated models of biomolecular interaction networks

MINT: the Molecular INTeraction database

Human protein reference database as a discovery resource for proteomics

BIND: the Biomolecular Interaction Network Database

DIP: the database of interacting proteins

KEGG for linking genomes to life and the environment

The Reactome Pathway Knowledgebase

EcoCyc: a comprehensive database resource for Escherichia coli

The Gene Ontology (GO) database and informatics resource

Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform